In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.Q: How does the new indication expand the eligible patient population?
In this case study, we describe a patient with HeFH who had a prior excellent response to statin but unable to take the same, and a less than expected response to PCSK9i, in whom initiation of bempedoic acid led to a substantial reduction of LDL-C. Our findings suggest that patients ...
IMPACT OF PAYER REJECTIONS AND OUT-OF-POCKET COSTS ON PATIENT ACCESS TO BEMPEDOIC ACID THERAPYdoi:10.1016/S0735-1097(24)03707-0Jimin HwangSouthwestern Medical Center, Dallas, TX, USAAnand GuptaSouthwestern Medical Center, Dallas, TX, USAEric D. Peterson...
Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trialsdoi:10.1016/j.atherosclerosis.2020.10.050P.B. DuellM. BanachA.L. CatapanoU. Laufs...
FACTORS THAT INFLUENCE BEMPEDOIC ACID-MEDIATED REDUCTIONS IN HIGH-SENSITIVITY C-REACTIVE PROTEIN: ANALYSIS OF POOLED PATIENT-LEVEL DATA FROM PHASE 3 CLINICAL TRIALSdoi:10.1016/S0735-1097(20)32543-2Erik S. G StroesHarold BaysMaciej BanachAlberico Catapano...
Factors that Influence Bempedoic Acid-Mediated Reductions in High-sensitivity C reactive Protein: Analysis of Pooled Patient-level Data from Phase 3 Clinical Trialsdoi:10.1016/j.jacl.2020.05.056Erik StroesHarold BaysMaciej BanachAlberico Catapano